Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?

As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular p...

Descripción completa

Detalles Bibliográficos
Autor principal: Lathia, Chetan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2002
Materias:
Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850863/
https://www.ncbi.nlm.nih.gov/pubmed/12364814
http://dx.doi.org/10.1155/2002/438745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850863/
https://www.ncbi.nlm.nih.gov/pubmed/12364814
http://dx.doi.org/10.1155/2002/438745

Ejemplares similares